Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
KALV
KALV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KALV News
Needham Raises Kalvista Price Target to $35
Jan 09 2026
Benzinga
KalVista Launches EKTERLY, Achieves $35M in First-Year Revenue
Jan 09 2026
Benzinga
Greenbrier Companies Inc Beats Q1 Earnings Estimates with $1.14 EPS and $706.1M Sales
Jan 09 2026
Benzinga
General Motors Faces $7.1 Billion Loss from EV Investments, Stock Drops
Jan 09 2026
Benzinga
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
Jan 09 2026
Benzinga
China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%
Jan 09 2026
NASDAQ.COM
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
KalVista Pharmaceuticals Receives Approval for EKTERLY (sebetralstat) in Japan
Dec 22 2025
SeekingAlpha
Marvell Reports Impressive Q3 Earnings, Alongside American Eagle, Microchip Technology, Box, and Other Major Stocks Rising on Wednesday
Dec 03 2025
Benzinga
Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Dec 03 2025
Benzinga
Significant Options Trading on Wednesday: WMT, KALV, MTDR
Nov 26 2025
NASDAQ.COM
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Nov 11 2025
NASDAQ.COM
KalVista Pharmaceuticals, Inc. (KALV) Announces Q3 Loss While Exceeding Revenue Projections
Nov 10 2025
NASDAQ.COM
KalVista Pharmaceuticals Unveils New Findings on Patient Satisfaction with EKTERLY® (sebetralstat) and Its Promise for Children Aged 2-11 at the ACAAI 2025 Annual Scientific Meeting
Nov 06 2025
Newsfilter
KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Its Board of Directors
Oct 02 2025
Newsfilter
"With EKTERLY's Successful Launch for HAE, Should Investors Monitor KalVista Stock?"
Sep 28 2025
NASDAQ.COM
Show More News
